Inhibition of FMS-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation

Journal of Leukocyte Biology

Volumn 90, Issue 4, 2011, Pages 811-817

  Dehlin, Mats ^a   Andersson, Sofia ^a   Erlandsson, Malin ^a   Brisslert, Mikael ^a   Bokarewa, Maria ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Flt3 ligand; Inflammation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD135 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE INJURY; BONE MARROW; BONE METABOLISM; CARTILAGE DEGENERATION; CELL MATURATION; DENDRITIC CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPLEEN; SYNOVITIS;

ANIMALS; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; BONE AND BONES; CARTILAGE; DENDRITIC CELLS; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; JOINTS; MICE; MICE, INBRED BALB C; PYRROLES; SYNOVITIS;

MUS;

EID: 80053373081     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1110640     Document Type: Article

References (39)

1. Firestein, G. S. (2003) Evolving concepts of rheumatoid arthritis. Nature 423, 356-361.
2. Hubbard, S. R., Till, J. H. (2000) Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398.
3. D'Aura Swanson, C., Paniagua, R. T., Lindstrom, T. M., Robinson, W. H. (2009) Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 317-324.
4. Juurikivi, A., Sandler, C., Lindstedt, K. A., Kovanen, P. T., Juutilainen, T., Leskinen, M. J., Maki, T., Eklund, K. K. (2005) Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann. Rheum. Dis. 64, 1126-1131.
5. Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B., Lee, D. M., Genovese, M. C., Utz, P. J., Steinman, L., Robinson, W. H. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642.
6. Murakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y., Shibuya, M. (2006) Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 108, 1849-1856.
7. Grosios, K., Wood, J., Esser, R., Raychaudhuri, A., Dawson, J. (2004) Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. 53, 133-142.
8. Koyama, K., Hatsushika, K., Ando, T., Sakuma, M., Wako, M., Kato, R., Haro, H., Sugiyama, H., Hamada, Y., Ogawa, H., Nakao, A. (2007) Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod. Rheumatol. 17, 306-310.
9. Ando, W., Hashimoto, J., Nampei, A., Tsuboi, H., Tateishi, K., Ono, T., Nakamura, N., Ochi, T., Yoshikawa, H. (2006) Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J. Bone Miner. Metab. 24, 274-282.
10. Eklund, K. K., Joensuu, H. (2003) Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann. Med. 35, 362-367.
11. Ghosh, D., Tsokos, G. C. (2010) Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 43, 48-55.
12. Soriano, P., Montgomery, C., Geske, R., Bradley, A. (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702.
13. Miyazaki, T., Sanjay, A., Neff, L., Tanaka, S., Horne, W. C., Baron, R. (2004) Src kinase activity is essential for osteoclast function. J. Biol. Chem.279, 17660-17666.
14. Takayanagi, H., Juji, T., Miyazaki, T., Iizuka, H., Takahashi, T., Isshiki, M., Okada, M., Tanaka, Y., Koshihara, Y., Oda, H., Kurokawa, T., Nakamura, K., Tanaka, S. (1999) Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J. Clin. Invest. 104, 137-146.
15. Pine, P. R., Chang, B., Schoettler, N., Banquerigo, M. L., Wang, S., Lau, A., Zhao, F., Grossbard, E. B., Payan, D. G., Brahn, E. (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244-257.
16. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337.
17. Faivre, S., Demetri, G., Sargent, W., Raymond, E. (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov.6, 734-745.
18. Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., Armand, J. P., Scigalla, P., Raymond, E. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35.
19. Maraskovsky, E., Daro, E., Roux, E., Teepe, M., Maliszewski, C. R., Hoek, J., Caron, D., Lebsack, M. E., McKenna, H. J. (2000) In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96, 878-884.
20. Lynch, D. H., Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R. E., Schuh, J. C. (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3, 625-631.
21. Esche, C., Subbotin, V. M., Maliszewski, C., Lotze, M. T., Shurin, M. R. (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58, 380-383.
22. Dehlin, M., Bokarewa, M., Rottapel, R., Foster, S. J., Magnusson, M., Dahlberg, L. E., Tarkowski, A. (2008) Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS ONE 3, e3633.
23. Brackertz, D., Mitchell, G. F., Mackay, I. R. (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 20, 841-850.
24. Verdrengh, M., Jonsson, I. M., Holmdahl, R., Tarkowski, A. (2003) Genistein as an anti-inflammatory agent. Inflamm. Res. 52, 341-346.
25. Jonsson, I. M., Verdrengh, M., Brisslert, M., Lindblad, S., Bokarewa, M., Islander, U., Carlsten, H., Ohlsson, C., Nandakumar, K. S., Holmdahl, R., Tarkowski, A. (2007) Ethanol prevents development of destructive arthritis. Proc. Natl. Acad. Sci. USA 104, 258-263.
26. Onai, N., Obata-Onai, A., Schmid, M. A., Ohteki, T., Jarrossay, D., Manz, M. G. (2007) Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat. Immunol. 8, 1207-1216.
27. Shortman, K., Liu, Y. J. (2002) Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2, 151-161.
28. Schellekens, G. A., Visser, H., de Jong, B. A., van den Hoogen, F. H., Hazes, J. M., Breedveld, F. C., van Venrooij, W. J. (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155-163.
29. Verdrengh, M., Tarkowski, A. (1997) Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect. Immun.65, 2517-2521.
30. Terato, K., Hasty, K. A., Reife, R. A., Cremer, M. A., Kang, A. H., Stuart, J. M. (1992) Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148, 2103-2108.
31. Holmdahl, R., Jansson, L., Larsson, A., Jonsson, R. (1990) Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand. J. Immunol. 31, 147-157.
32. Lebre, M. C., Tak, P. P. (2009) Dendritic cells in rheumatoid arthritis: which subset should be used as a tool to induce tolerance? Hum. Immunol.70, 321-324.
33. Ding, C., Cai, Y., Marroquin, J., Ildstad, S. T., Yan, J. (2009) Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. J. Immunol. 183, 7140-7149.
34. Vinay, D. S., Kim, C. H., Chang, K. H., Kwon, B. S. (2010) PDCA expression by B lymphocytes reveals important functional attributes. J. Immunol.184, 807-815.
35. Liu, K., Nussenzweig, M. C. (2010) Origin and development of dendritic cells. Immunol. Rev. 234, 45-54.
36. Tussiwand, R., Onai, N., Mazzucchelli, L., Manz, M. G. (2005) Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity. J. Immunol.175, 3674-3680.
37. Schiavoni, G., Mattei, F., Sestili, P., Borghi, P., Venditti, M., Morse III, H. C., Belardelli, F., Gabriele, L. (2002) ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8α(+) dendritic cells. J. Exp. Med. 196, 1415-1425.
38. Bigley, V., Haniffa, M., Doulatov, S., Wang, X. N., Dickinson, R., McGovern, N., Jardine, L., Pagan, S., Dimmick, I., Chua, I., et al. (2011) The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J. Exp. Med. 208, 227-234.
39. Dewar, A. L., Cambareri, A. C., Zannettino, A. C., Miller, B. L., Doherty, K. V., Hughes, T. P., Lyons, A. B. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105, 3127-3132.